Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

NCT04081688 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped accrual goal met

Conditions

Refractory Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions

DRUG: Atezolizumab 1200 MG in 20 ML Injection
RADIATION: Stereotactic Body Radiation Therapy
DRUG: Varlilumab 3 mg/kg

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]